EVENTS|NEWS|CONTACT|DONATE

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Read Our Newsletter

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

News in Gastric Cancer

News from around the world, curated by the Gastric Cancer Foundation.

enhertu

Enhertu granted Priority Review in the US for the treatment of HER2-positive metastatic gastric cancer

AstraZeneca and Daiichi Sankyo were granted priority review by the FDA for Enhertu to treat HER2-positive gastric or gastroesophageal junction cancer, with a decision expected early next year.

enhertu, gastroesophageal, HER2

Share Post:

New Grant Awarded to USC for Study of Epigenetic Targets in Gastric Cancer

CARsgen Therapeutics Granted Orphan Drug Designation by the US FDA for CAR-T Cells for the Treatment of Gastric and Gastroesophageal Junction Cancers

Social Media

Newsroom

For press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org

Categories

Foundation News
Press Releases
Research News

Tags

adenocarcenoma advanced stage alcohol antibody biomarker blood chemoradiotherapy chemotherapy clinical trial clinical trials detection drugs endoscopy Epstein-Barr esophagogastric FDA gastrectomy gastric cancer registry gastroesophageal genes heartburn helicobacter pylori HER2 immunotherapy keytruda lonsurf metastatic nutrition peritoneal postoperative prevention proton pump inhibitor recovery recurrence research risk screening side-effects studies surgery survival treatment tumor virus women

Gastric Cancer Foundation

Tax ID 27-2978173

info@gastriccancer.org

PO Box 338
Millbrae, CA 94030

For Deliveries:
Gastric Cancer Foundation
501 Broadway, #338
Millbrae, CA 94030-1907

Site Map

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Social Feed

Gastric Cancer Foundation

2 weeks ago

The Gastric Cancer Foundation has just published its first comprehensive Impact Report. The report highlights our efforts to accelerate research innovation and provide resources to support patients and families.We encourage you to take a look to see what we’ve accomplished together and consider contributing to our vital work. Together, we will defeat gastric cancer. gastriccancer.org/impact-report/ ... See MoreSee Less

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

2 weeks ago

Adding immunotherapy to chemotherapy has been a “significant advance” in treating gastric cancer, but questions remain, says Samuel Cytryn, MD, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center in New York.www.oncologynewscentral.com/article/most-significant-advance-in-gastric-cancer-care-leads-to-new-... ... See MoreSee Less

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

3 weeks ago

In a trial, treating gastric cancer patients with chemoradiotherapy prior to surgery did not boost survival rates. ... See MoreSee Less

Survival Rates with Preoperative Chemoradiotherapy for Resectable Gastric Cancer

www.physiciansweekly.com

The following is a summary of

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

4 weeks ago

I-Mab’s bispecific antibody targeting CLDN18.2 showed promising efficacy as a solo treatment for gastric cancer patients in an early trial.www.nasdaq.com/articles/i-mab-reports-promising-results-phase-1-study-givastomig-gastric-cancer ... See MoreSee Less

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

4 weeks ago

For some patients with gastric cancer, the risks outweigh the benefits of checkpoint-inhibiting immunotherapy drugs, the U.S. Food and Drug Administration says. ... See MoreSee Less

FDA ODAC Finds Limited Benefit for Checkpoint Inhibitors in Low PD-L1 Gastric Cancer

www.targetedonc.com

The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in first-line advanced gastric cancer with PD-L1 expression less than 1.

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Subscribe to Our Newsletter

We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.

© 2024 Gastric Cancer Foundation. All Rights Reserved.

EVENTS | NEWS | CONTACT | DONATE

Please join with us to fuel the next wave of progress.

Your support today will honor the memories of those we have lost and create much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.

Please join with us to fuel the next wave of progress. Support our 2024 Fundraising Campaign.

Your support today will honor the memories of those we have lost and create much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.

Together, we will defeat stomach cancer.

Together, we will defeat stomach cancer.

MORE INFO DONATE

X